title: [Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
abstract: The use of cardiovascular secondary prevention medications in patients with acute coronary syndromes was compared in 4 sequential observational surveys carried out in France from 1995 to 2000. The Usik 1995 and Usic 2000 surveys included patients admitted for acute myocardial infarction, while the 2 Prevenir surveys (1998 and 1999) assessed the medications prescribed in patients with acute coronary syndromes. Antiplatelet agents were prescribed in 91% of the patients in 1995, 93% in 1998 and 1999 and 96% in 2000; for beta-blockers, the respective figures were: 64%, 68%, 75% and 76%. For ACE-Inhibitors, the figures were: 46%, 41%, 41% and 50%. For statins, the prescription increased from 10% to 36%, 59% and 64%. In 1995, 8% of the patients received both antiplatelet agents, beta-blockers and statins (4% of them also had an ACE-Inhibitor); in 2000, the respective figures were 53% and 27%. The results of the recent trials of secondary prevention medications have had a considerable impact on real-life practice in France during the late 1990s.
authors.affiliation: Département de cardiologie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. nicolas.danchin@egp.ap-hop-paris.fr
authors.forename: N
authors.initials: N
authors.lastname: Danchin
authors.forename: G
authors.initials: G
authors.lastname: Hanania
authors.forename: O
authors.initials: O
authors.lastname: Grenier
authors.forename: L
authors.initials: L
authors.lastname: Vaur
authors.forename: E
authors.initials: E
authors.lastname: Amelineau
authors.forename: P
authors.initials: P
authors.lastname: Guéret
authors.forename: D
authors.initials: D
authors.lastname: Blanchard
authors.forename: J
authors.initials: J
authors.lastname: Ferrières
authors.forename: N
authors.initials: N
authors.lastname: Genès
authors.forename: J M
authors.initials: JM
authors.lastname: Lablanche
authors.forename: C
authors.initials: C
authors.lastname: Cantet
authors.forename: J P
authors.initials: JP
authors.lastname: Cambou
mesh_terms: D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy* / Q000517:prevention & control; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D004363:Drug Utilization / Q000639:trends; D005260:Female; D005602:France; D019538:Health Care Surveys / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000517:prevention & control; D010351:Patient Discharge; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
vernacular_title: Evolution du traitement de sortie après hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000: données des études Usik 1995, Prévenir 1 et 2 et Usic 2000.